Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Andrographis paniculata extract is a herbal preparation derived from the plant Andrographis paniculata (family Acanthaceae), commonly known as "King of Bitters." The primary active compound in the extract is andrographolide—a diterpene lactone—along with other diterpenoids and flavonoids. Traditionally used in Ayurvedic and Chinese medicine as an immunostimulant and antipyretic agent[1][3][5], it has been clinically studied for its potential anti-inflammatory[1][5], antiviral[8], antibacterial[5], immunomodulatory[8], and antipyretic activities. Research suggests that its mechanism involves reducing pro-inflammatory cytokines to exert anti-inflammatory effects[5]. It has been investigated for use in respiratory tract infections (such as the common cold), osteoarthritis[1], hypertriglyceridemia[1], inflammatory bowel disease[4], and other inflammatory conditions. However, robust clinical evidence supporting these uses remains limited.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on andrographis paniculata extract.